CRISPR Therapeutics AG (CRSP): Shareholders' Equity
$1.92B
As of 2025-12-31
$1.75B
As of 2026-06-30
+0.8%
3-year compound annual growth
+2.9%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.92B | -0.5% | 2026-02-12, Balance as of period end |
| 2024-12-31 | $1.93B | +2.6% | 2026-02-12, Balance as of period end |
| 2023-12-31 | $1.88B | +0.4% | 2026-02-12, Balance as of period end |
| 2022-12-31 | $1.88B | -21.8% | 2025-02-11, Balance as of period end |
| 2021-12-31 | $2.40B | +44.2% | 2024-02-21, Balance as of period end |
| 2020-12-31 | $1.66B | +77.2% | 2023-02-21, Balance as of period end |
| 2019-12-31 | $939.42M | +139.5% | 2022-02-15, Balance as of period end |
| 2018-12-31 | $392.19M | +108.8% | 2021-02-16, Balance as of period end |
| 2017-12-31 | $187.83M | -19.3% | 2020-02-12, Balance as of period end |
| 2016-12-31 | $232.85M | n/m | 2018-03-08, Balance as of period end |
| 2015-12-31 | -$29.10M | n/a | 2017-03-10, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $1.92B | -0.5% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | -$187.76M | n/m |
| Dyadic International Inc (DYAI) | 2025-12-31 | $1.23M | -50.1% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $752.60M | +2.6% |
| Ocugen, Inc. (OCGN) | 2025-12-31 | -$12.17M | n/m |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $120.87M | -21.1% |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | -$1.42M | n/m |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | $53.55M | n/m |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $168.77M | +516.2% |
Compare CRSP, SRZN, DYAI, CGON side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗